Biological therapy for non-small-cell lung carcinoma;Biologická léčba nemalobuněčného karcinomu plic

Interni Medicina pro Praxi

Volumn 13, Issue 7, 2011, Pages 292-295

  Skřičková, Jana ^a   Babičková, Lenka ^a   Tomísková, Marcela ^a   Kadlec, Bohdan ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Biological therapy; Non small cell lung carcinoma (NSCLC); Predictive factors; Prognostic factors

Indexed keywords

BIOLOGICAL THERAPY; CZECH REPUBLIC; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; PROGNOSIS; REVIEW;

EID: 83655196982     PISSN: 12127299     EISSN: 18035256     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. http://www.svod.cz
2. Ginsberg RJ. Lung Cancer. London, BC Decker Hamilton, 2002: 175.
3. Marel M, Skácel Z, Špásová I, et al. Diagnostika a léčba nemocných s plicním karcinomem na oddělení TRN ve FN Motol v letech 1998-2003. Stud Pneumol Phtiseol 2004; 64: 289-294.
4. Martins SJ, Pereira JR. Clinical Factors and Prognosis in Non-Small Cell Lung Cancer. Am J Clin Oncol 1999; 22: 453-457.
5. Sirohi B, Ashley S, Bortin A, et al. Early Response to Platinum - Based First - Line Chemotherapy in Non-Small Cell Lung Cancer May Predict Suvival. J Thorac Oncol 2007; 2: 735-740.
6. Molina JR, Dusi AA, Jett JR. Advances in Chemotherapy of Non-small Cell Lung Cancer. Chest 2006; 130: 1211-1219.
7. Dy GK, Adjei AA. Novel Targets for Lung Cancer Therapy: Part II. J Clin Onco.
8. Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003; 41: S9-S14.
9. Mendelsohn J. Targeting the Epidermal Growth Factor Receptor for Cancer Therapy. Journal of Clinical Oncology 2002; 20 (suppl 15): 1-13.
10. http://www.cancer.gov/clinicaltrials/results/cetuximab-NSCLC0608
11. Jonson DH. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer 2003; 41: S23-S28.
12. Baselga J, Kris M, Yano S, et al. Phase II trial (IDEAL a and IDEAL 2) of ZD1839 ("IRESSA" ) in locally advanced or metastatic non-small-cell lung cancer patients. ESMO, Nice, France, October 18-22, 2002.
13. Fukuoka M, Yano S, Giacone G, et al. A multi-institutional randomized phase II trial of gefitinib for previously terated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003; 21: 2237-2246.
14. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003; 290: 2149-2158.
15. Pešek M, Skřičková J, Kolek V, et al. Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Studia Pneumologica et Pthiseologica. 2009, 69(2): 61-68.
16. Pešek M, Teřl M, Krákorová G. Gefitinib - zkušenosti s biologicky cílenou terapií nemalobuněčného karcinomu plic. Stud Pneumol Phtiseol 2004; 64: 117-122.
17. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
18. Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med 2004; 350: 2129-2139.
19. Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: a randomised Phase III trial (INTEREST). Lancet 2008; 372: 1809-1818.
20. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 2004; 22: 777-784.
21. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 2004; 22: 785-794.
22. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 2009; 361(10): 947-957.
23. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
24. Skřičková J, Pešek M, Zatloukal P, et al. Klinický registr TARCEVA. Klin Okol 2010; 23(5): 361-363.
25. Tomíšková M, Skřičková J, Štícha M. Klinické zkušenosti s léčbou erlotinibem u nemocných s pokročilým nemalobuněčným karcinomem plic. Onkologie 2010; 4: 270-276.
26. Cappuzzo F, Stelmakh T, Cicenas S, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The Lancet Oncology 2009, 11: 521-529.
27. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002; 29: 10-14.
28. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
29. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27(14): 2415.
30. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacuzimab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
31. Laskin J, Crino L, Tsai C, et al. MO19390 (SAiL): first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC)-outcome by chemotherapy regimen [abstract C2.5]. J Thorac Oncol 2009; 4(Suppl 1): S359.